Posted by Michael Wonder on 04 Aug 2021
FDA grants breakthrough device designation status for Hancock Jaffe's VenoValve
3 August 2021 - VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe chronic venous insufficiency in the deep veins of their legs.
Hancock Jaffe Laboratories today announced that the U.S. FDA has granted breakthrough device designation status to the VenoValve, the Company's lead product, which is currently set to begin its U.S. pivotal trial.
